Embed Size (px)
DESCRIPTION
healthcare, pharmaceutical industry, investment, rate of return, human capital theory, who,sustainable development, health expenditure, hospital, finished product, api, value chain, gdp, active hospital beds, healthcare partnership, cancer center, radiotherapy
Citation preview
Business Opportunities in the
Iranian Pharmaceutical Industry
Tamin Pharmaceutical Investment Company
Iranian Pharma Market - Structure (2012)
.57%
31%
12%
GenericBrandOTC
Iranian Pharma Market- Supply (2012)
.
96.1%
3.9%
Internally manufactured Imported
Iranian Pharma Market- Sales (2012)
Column1
Internally ManufacturedImported.
Value(Billion USD)
Volume(Billion)
Total Share(Value)
Total Share(Volume)
Domestic Production 3.2 33 64 % 96.1%
Imported 1.8 1.3 36 % 3.9%
Total 5.1 34.3 100% 100%
Iranian Pharma Market- Market Growth
Column1
Internally ManufacturedImported.
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
332 418 574 663 832 1013 1196 1474 1915 2229 2715 3300
8000
72 107 163 215 321 426 558764
11991276
15311800
Domestic Production Imported
mill
ion
USD
Tamin PharmaceuticalInvestment Company - TPICO• TPICO was established in 2003 as a corporate entity for the
governance and management of independently managed pharmaceutical companies in the portfolio of Social Security Investment Company.
TPICO
• Currently TPICO manages 32 subsidiary pharmaceutical companies which encompass the whole pharma value chain.
TPICO
R&D
API
FP
Distribution
Commercial Trade
Retailing
32 Companies 8000 HR 900 Products 810 FPs 90 APIs
TPICO
FP 34.07% API 70% Dist. 33.3% Vet. 41% Exp. 40%
Generals
Market Share
TPICO Value Chain
.
TPICO
R&D API FP Distribution Trade & Retailing
One Central R&D
Ten Companies
Twelve Companies
Four Companies
Three Companies
1385 1386 1387 1388 1389 1390 1391 13924,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
22,000
24,000
622758
945
1190
1488
1695
1977
2264
Annual Sales of TPICOUSD (Million)
2012-2013
TPICO International Cooperation
Tamin Central R&D• Biotechnology Dept.• Peptide & Protein Dept.• Narcotics Dept.• Herbal and Natural
Products Dept.• Drug Design Dept.• LVHV Dept.• Chemical Synthesis Dept.• Nano Drugs• NDDS
Group PipelineId
eas
Mar
ket
726 Molecules
High Tech Products with an Annual Market Value
of 1 billion USD
Future Projects
.
Development of high value medicines for both domestic
use and exports
Future Projects
.
Tamin Pharmaceutical City
Future Projects
.
Tamin Plasma Fractionation Plant
Future Projects
.
Tamin Human and Veterinary Vaccine Plant
Business Opportunities in the
Iranian Hospital Industry
